Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Protective Efficacy of Seasonal LAIV Using a Human Challenge Model
NCT02950688Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in influenza (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of any reactogenicity events after administration of seasonal LAIV at Day 180, Frequency of significant increases in nasal secretion hemagglutination (HA)-specific antibody at Day 84 and 9 more. Status: withdrawn.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT02950688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950688.